Laura Piccinini Named as Chief Executive Officer at Respiratory Motion, Inc.

Watertown, MA. July 14th, 2020.  Respiratory Motion INC. (RMI) today announced the appointment of Laura Piccinini as Chief Executive Officer effective immediately. Piccinini served on the RMI Board of Directors since the beginning of 2020. She succeeds Dr. Jenny Freeman, CEO since 2012. 

Laura is an executive with an outstanding career in the medical device industry including successful leadership assignments across multiple market segments. Most recently, she served as Vice President & General Manager of Envista following Danaher’s IPO of the business. Previously, she led the Global Commercial Operations Department of Nobel Biocare Systems

Over a career spanning 25 years, Laura has held senior executive roles with full P&L responsibility at Nellcor, Nellcor Puritan Bennett, Mallinckrodt, and Danaher. She held President roles at Tyco, Covidien, Stryker, and Acelity. She has specific experience in respiratory monitoring technologies and an education and clinical background in intensive care patient management.

“We are delighted to welcome Laura Piccinini as RMI’s CEO” commented Chas Taylor, Chairman of RMI. “Laura is a highly regarded executive with a proven track record of building great businesses and creating shareholder value. We are confident that Laura’s vision, operational discipline, and commercial acumen make her the ideal leader for RMI, we are excited to see her lead the company to commercial success.”

“I am delighted to have the opportunity to lead the RMI team. The company has a unique approach to respiratory monitoring, and an exceptionally strong differentiated product portfolio developed around customer needs,” commented Piccinini “RMI has an exceptional potential to drive sustainable growth and profitability while, continuing to deliver market-leading technology to help our clinician customers provide better clinical outcomes for patients.” 

Founder Dr. Jenny Freeman commented "I am very pleased that Laura has been appointed as CEO, the company is now in a position where we can benefit from her skills as we take RMI to the next level."

Board of Directors Press Release

Watertown, MA. July 2, 2020.  Respiratory Motion today announced the appointment of Chas Taylor and Bob Smouse, M.D., F.A.C.R. to the Board of Directors, Chas Taylor has been named Chairman of the Board, and Bob Smouse the President of the company, overseeing day to day operations.

“Respiratory Motion has a technology that can save lives for patients across many care areas in the hospital,” said Dr. Smouse. “In my years of clinical practice, it is rare to see technologies that can become the new standard of care like the RMI system. I am excited to play a role in bringing this groundbreaking technology to clinicians and patients.”

Dr. Smouse was most recently the founder, CEO and CMO of BrightWater Medical, a medical device company that commercialized an innovative urologic and biliary catheter to stent technology and was acquired by Merit Medical in 2019.  Dr. Smouse has served as a medical consultant and Scientific Advisory Board member for many industry device leaders.  In addition to his industry activity, Dr. Smouse has more than 25 years clinical experience in interventional radiology including leading academic training programs and many important clinical research studies.

“Respiratory Motion is a groundbreaking technology that creates a new category of respiratory monitoring,” said Mr. Taylor. “I see this as an opportunity to build a strong successful business while introducing a product that improves patient outcomes.”

Mr. Taylor has over 30 years of experience in the medical technology industry. Recently he was the CEO of Veryan Medical, a Co-founder and Director of Novate Medical, and a Director of BrightWater Medical.  All three of these companies were acquired in the last three years. Previously, Mr. Taylor was the Co-founder of MedNova, which was acquired by Abbott Laboratories. Prior to founding and leading these companies, he had a long career with Bard Cardiovascular and General Surgical products where he had roles of increasing responsibility in general management and international sales and marketing.

We are delighted to have Chas and Bob join the Board of Directors at Respiratory Motion,” said Jaideep Mehta, MD, MBA, FASA, board member and previous chairman.  “They bring a track record of success and experience that will help Respiratory Motion grow and thrive.

About Respiratory Motion, Inc.

Respiratory Motion, Inc., headquartered in Watertown, MA., is the global leader in innovative Minute Ventilation Monitoring, useful across a wide variety of patient populations and environments to assess respiratory function and provide early warning of respiratory collapse. Our mission is to help clinicians save lives, improve patient care, and reduce healthcare costs. www.respiratorymotion.com

Respiratory Motion, Inc. Awarded National Group Breakthrough Technologies Purchasing Contract by Premier

Premier Hospitals now provide Respiratory Motion’s ExSpiron™ Respiratory Monitor to improve patient safety

Waltham, MA – September 18, 2018 – Respiratory Motion, Inc. is announcing the award of a group purchasing agreement as a Breakthrough Technology with Premier Inc., a leading healthcare improvement company.  Premier unites an alliance of approximately 4,000 U.S. hospitals and 165,000 other providers who will now have direct access to Respiratory Motion’s ExSpiron™ , the first and only Minute Ventilation Monitor for all patients. The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier. In response to increasing pressure to improve the safety of patients, especially those requiring opioids, hospitals have sought solutions to meet this growing need. Deemed by Premier to be a significant advancement in monitoring patients’ breathing, the ExSpiron™ was approved through Premier’s Technology Breakthroughs program to give members immediate access to this technology without waiting for the next contracted supplier competitive bidding cycle.  

See the full release here.

Respiratory Motion, Inc. is excited to announce the FDA clearance for the ExSpiron™ 1Xi Minute Ventilation monitor for the use in Pediatric Patients

· Minute Ventilation (MV) is the earliest indicator of insufficient breathing. The ExSpiron is the first and only MV monitor capable of providing continuous, non-invasive measurements for individuals not on a ventilator.

Respiratory Motion, Inc. (Waltham, Massachusetts, USA) reported today that FDA clearance was received for the newest version of its ExSpiron Minute Ventilation (MV) monitoring system on Friday March 16th and announced its plan to launch the new ExSpiron at the Society for Pediatric Anesthesia-American Academy of Pediatrics in Phoenix, March 23-25.

Respiratory failure can occur anywhere in the hospital and early detection can often make the difference between life and death. MV monitoring is the most direct measure of respiratory status, providing the earliest warning of changes in respiratory status. Sufficient time to act is crucial in preventing bad outcomes. Respiratory Motion’s ExSpiron is the first and only continuous Minute Ventilation Monitor that has been cleared for broad use in hospital and ancillary medical settings.

See the full release here.

Respiratory Motion, Inc. and Corestone Biosciences (Beijing) Co., Ltd., have established a Joint Venture Company to deliver monitoring solutions to Chinese health care market and the globe.

Respiratory Motion, Inc. and Corestone Biosciences (Beijing) Co., Ltd., have established a Joint Venture Company to deliver monitoring solutions to Chinese health care market and the globe.

Respiratory Motion, Inc. (Waltham, Massachusetts, USA) the global leader in minute ventilation monitoring and Corestone Biosciences Co., Ltd., an innovative medical device company in anesthesia and analgesia headquartered in Beijing, China have entered into an agreement to form a Joint Venture Company (JV). The JV will offer a new generation of Respiratory Volume Monitors based on Respiratory Motion’s ExSpiron platform, along with other novel critical care solutions for hospital and home markets. The JV will operate out of Zhengzhou in Henan province and through a broad network to deliver its services across China and globally.

See the full release here.